Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | PDE4A | P27815 | 14/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12995884 | 0.89 | KCNH2 (0.81) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2331333 | 0.88 | KCNH2 (0.79) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1566354 | 0.87 | KCNH2 (0.77) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5340317 | 0.86 | KCNH2 (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL29496418 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL4950462 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| Mk-0873 SCHEMBL29372259 | 0.86 | PDE4A (1.00) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1566248 | 0.86 | KCNH2 (0.76) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14336538 | 0.86 | KCNH2 (0.75) | KCNH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12198465 | 0.86 | PDE4A (0.84) | KCNH2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436290-B1 | ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR | MERCK FROSST CANADA LTD (CA) | 2013-09-18 | — | — | EP | claimed |
| EP-2305677-A1 | Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor | Merck Frosst Canada Limited (CA) | 2011-04-06 | — | — | EP | claimed |
| EP-1562588-A4 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-20060069115-A1 | Use of pde4 inhibitors as adjunct therapy for psychiatric disorders | SCOLNICK EDWARD M | 2006-03-30 | — | — | US | claimed |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | MERCK FROSST CANADA LTD. (CA) | 2006-02-23 | — | — | US | claimed |
| EP-1592419-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | Merck Frosst Canada & Co. (CA) | 2005-11-09 | — | — | EP | claimed |
| EP-1562588-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20050070569-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-03-31 | — | — | US | claimed |
| EP-1436290-A1 | ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR | Merck Frosst Canada & Co. (CA) | 2004-07-14 | — | — | EP | claimed |
| WO-2004047836-A1 | USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | claimed |
| WO-2004045508-A2 | USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-06-03 | — | — | WO | claimed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | claimed |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2003-06-19 | — | — | US | claimed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| US-6743802-B2 | ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003018579-A1 | ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114478-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | PDE4A, PDE3B, PDE4B | KCNH2 756/4885PDE4A 1/4885PDE4B 3/4885 |
| US-20060040981-A1 | Use of phosphodiesterase-4 inhibitors as enhancers of cognition | PDE4A, PDE4B, PDE4C | KCNH2 2057/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20050070569-A1 | Alkyne-aryl phosphodiesterase-4 inhibitors | PDE4A, PDE3B, PDE4B | KCNH2 858/4885PDE4A 1/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.